Literature DB >> 3284760

The alveolitis of hypersensitivity pneumonitis.

U Costabel1.   

Abstract

In the pathogenesis of hypersensitivity pneumonitis (HP) several immune mechanisms are involved. The initial phase, 4-48 h after antigen inhalation, appears to be immune complex mediated and is characterized by an early increase in bronchoalveolar lavage (BAL) neutrophils and the histopathologic features of oedema, neutrophil infiltration of the alveolar wall, and vasculitis. After 12 h to several days, the immune response possibly shifts to a cell-mediated reaction, and the alveolitis consists of cytotoxic effector cells as well as suppressor cells which may be required to modulate the B cell response of antibody production by plasma cells. In this phase, lymphocytes of the OKT8 positive phenotype, natural killer cells, and occasionally a few plasma cells are increased in BAL fluid. The characteristic histopathologic finding is a mononuclear infiltrate consisting of lymphocytes, plasma cells, and foamy histiocytes. After weeks to months, a delayed type hypersensitivity reaction may lead to a slight predominance of OKT4 positive cells in BAL fluid and to granuloma formation. Finally, after months to years, repeated immune-mediated injury to the alveolar wall with release of proteolytic enzymes and fibroblast growth factors may result in pulmonary fibrosis and end stage lung with concomitant increase in BAL neutrophils as in other fibrotic diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284760

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  [Bronchoalveolar lavage].

Authors:  M Tötsch; J Guzman; D Theegarten; K W Schmid; U Costabel
Journal:  Pathologe       Date:  2007-09       Impact factor: 1.011

Review 2.  Immunophenotyping of bronchoalveolar lavage lymphocytes.

Authors:  R J Harbeck
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 3.  Characteristics and clinical significance of the lymphocytic alveolitis in interstitial lung disorders.

Authors:  G A Rossi; B Balbi; S Lantero; C Ravazzoni
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 4.  Hypersensitivity pneumonitis.

Authors:  Ulrich Costabel; Yasunari Miyazaki; Annie Pardo; Dirk Koschel; Francesco Bonella; Paolo Spagnolo; Josune Guzman; Christopher J Ryerson; Moises Selman
Journal:  Nat Rev Dis Primers       Date:  2020-08-06       Impact factor: 52.329

5.  Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage (BAL) fluids of extrinsic allergic alveolitis.

Authors:  N Shijubo; K Imai; K Shigehara; M Hirasawa; M Tsujisaki; Y Hinoda; S Abe
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

6.  Differences in expression of monocyte/macrophage surface antigens in peripheral blood and bronchoalveolar lavage cells in interstitial lung diseases.

Authors:  H C Hoogsteden; P T van Hal; J M Wijkhuijs; W Hop; C Hilvering
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 7.  Takes your breath away--the immunology of allergic alveolitis.

Authors:  C McSharry; K Anderson; S J Bourke; G Boyd
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

8.  Experimental extrinsic allergic alveolitis and pulmonary angiitis induced by intratracheal or intravenous challenge with Corynebacterium parvum in sensitized rats.

Authors:  E S Yi; H Lee; Y K Suh; W Tang; M Qi; S Yin; D G Remick; T R Ulich
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

9.  Relationship between plasma cell levels and profile of bronchoalveolar lavage fluid in patients with subacute extrinsic allergic alveolitis.

Authors:  M Drent; S Wagenaar; H van Velzen-Blad; P G Mulder; H C Hoogsteden; J M van den Bosch
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

10.  Utility of Exhaled Nitric Oxide Fraction for the Diagnosis of Hypersensitivity Pneumonitis.

Authors:  I Ojanguren; M J Cruz; A Villar; M Barrecheguren; F Morell; X Muñoz
Journal:  Lung       Date:  2015-11-13       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.